TearLab Corporation to Release Q3 2011 Financial Results on November 10, 2011

SAN DIEGO, Oct. 31, 2011 (GLOBE NEWSWIRE) -- TearLab Corporation TEAR TLB expects to announce its Q3 2011 financial results before the market opens on Thursday November 10, 2011.

TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. This call will be held at 8:30am Eastern at 877-303-1593 (within the United States and Canada)

Date: November 10, 2011

Time: 8:30 AM ET

Listen via Internet: http://www.tearlab.com/us/shareholder.htm/

Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=50509&k=A6EFEE32

Telephone:     877-303-1593

For those wishing to listen to a recording of the call via telephone, a replay will be made available by 11:30am Eastern after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone 855-859-2056 (toll free) or 404-537-3406 and enter conference ID: 23754946 when prompted.

About TearLab Corporation TearLab Corporation (www.tearlab.com) develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab(r) Osmolarity Test, that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care, is the first assay developed for the award winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

Forward-Looking Statements This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press released include predictions regarding the sufficiency of current cash and cash equivalents to fund operations for 12 months or more, intent to submit a revised CLIA waiver application, building sales in Europe and Canada, seeking CLIA waiver and Medicare reimbursement, and the future commercial adoption of the TearLab Osmolarity System. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.